Figure 3.
Cumulative incidences of molecular responses. Cumulative incidence of MMR (A) and BCR::ABL1IS ≤1% (B). ∗Nonresponders were censored at their last molecular assessment date. †Discontinuation from treatment for any reason without previous achievement of MMR was considered a competing event. ‡Based on 142 of 157 patients (90.4%) who received asciminib and 72 of 76 (94.7%) who received bosutinib with BCR::ABL1IS >1% at baseline. §Discontinuation from treatment for any reason without previous achievement of BCR::ABL1IS ≤1% was considered a competing event. ||The probability of BCR::ABL1IS ≤1% was not estimable from week 104 onward because no patients were eligible to achieve BCR::ABL1IS ≤1%. NE, not estimable.

Cumulative incidences of molecular responses. Cumulative incidence of MMR (A) and BCR::ABL1IS ≤1% (B). ∗Nonresponders were censored at their last molecular assessment date. †Discontinuation from treatment for any reason without previous achievement of MMR was considered a competing event. ‡Based on 142 of 157 patients (90.4%) who received asciminib and 72 of 76 (94.7%) who received bosutinib with BCR::ABL1IS >1% at baseline. §Discontinuation from treatment for any reason without previous achievement of BCR::ABL1IS ≤1% was considered a competing event. ||The probability of BCR::ABL1IS ≤1% was not estimable from week 104 onward because no patients were eligible to achieve BCR::ABL1IS ≤1%. NE, not estimable.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal